Denali Therapeutics

CIK 0001714899 · Biotech · Public

Small molecule therapeutics that cross the blood-brain barrier to treat neurodegenerative diseases

denalitherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$500M
1 Form D · Mar 2024
32 months since last filing
Contracts
—
No federal contracts on record
Patents
40
14 granted · 26 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$499,732,711
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1128Moderna—$556M
1129Mariana Oncology——
1130OMVAX, INC.——
1131Denali Therapeutics—$500M
1132MS Biotech Holdings, Inc.—$59M
1133PROLACTA BIOSCIENCE INC—$65M
1134CalciMedica Subsidiary, Inc.—$67M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Jennifer CookDirector
  • Jay FlatleyDirector
  • Erik HarrisDirector
  • Carole HoExecutive Officer
  • Peter KleinDirector
  • Steve KrognesDirector
  • Vicki SatoDirector
  • David SchenkeinDirector
  • Alexander SchuthExecutive Officer
  • Marc Tessier-LavigneDirector
  • Nancy ThornberryDirector
  • Ryan WattsDirector · Executive Officer

Patents

USPTO · 14 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.